Summary of Significant Accounting Policies (Details)			1 Months Ended			12 Months Ended
	Oct. 11, 2024 USD ($)	Jul. 19, 2024 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Nov. 30, 2022 USD ($) $ / shares shares	Apr. 30, 2020 USD ($)	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Oct. 31, 2024 shares	Dec. 31, 2021 USD ($)
Policies
Net Income (Loss)						$ (190,426,000)	$ (434,801,000)	$ (547,799,000)
Accumulated deficit						2,567,862,000	2,377,436,000
Cash, cash equivalents and restricted cash						945,587,000	642,095,000	466,091,000		$ 84,614,000
Marketable securities						22,689,000	236,882,000
Short-term Credit Line, outstanding balance						80,362,000	$ 80,402,000
Borrowings under credit facility								$ 30,000,000
Collateral amount						150,000,000.0
Remaining borrowing capacity						$ 20,000,000.0
Common stock, shares issued | shares			4,550,000	13,144,500		132,646,000	119,581,000		7,532,300
Stock issued (in dollars per share) | $ / shares			$ 55	$ 35
Payment of offering expenses			$ 400,000	$ 500,000
Proceeds from issuance of common stock			$ 235,800,000	433,200,000
Convertible Notes
Policies
Outstanding principal balance		$ 287,500,000			$ 287,500,000
Per annum interest rate (as a percent)	2.25%	2.25%			2.25%
Percentage of principal amount converted	100.00%	100.00%			100.00%
Convertible Notes Payable	$ 287,400,000
Convertible to shares of common stock	7,500,000				7,411,704
Proceeds from notes payable	$ 100,000
Line Of Credit-UBS
Policies
Borrowings under credit facility				$ 30,000,000.0
Collateral amount						$ 150,000,000.0
Remaining borrowing capacity						$ 20,000,000.0
Equity offering
Policies
Common stock, shares issued | shares			4,550,000